Name | 2-(4-Brom-phenyl)-2,3-dihydro-1H-perimidin |
---|---|
Synonyms |
1h-naphth[1,2-e][1,3]oxazine,2-(4-bromophenyl)-2,3-dihydro
2-(4-bromo-phenyl)-2,3-dihydro-1H-perimidine 2-<4-Brom-phenyl>-2.3-dihydro-1H-naphth<1.2-e>-1.3-oxazin 2-(4-bromo-phenyl)-2,3-dihydro-1H-naphth[1,2-e][1,3]oxazine 2-(4-bromophenyl)-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazine |
Description | Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 µM. Hepln-13 can be used for the research of metastatic prostate cancer[1]. |
---|---|
Related Catalog | |
Target |
IC50: 0.33 μM (Hepsin) |
In Vitro | Hepln-13 (10 µM; 2 hours; 293 cells) inhibits cleavage[1]. Western Blot Analysis[1] Cell Line: 293 cells Concentration: 10 µM Incubation Time: 2 hours Result: Inhibited cleavage. |
In Vivo | HepIn-13 displays dose dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes and blocks prostate cancer metastasis[1]. |
References |
Density | 1.444g/cm3 |
---|---|
Boiling Point | 533.3ºC at 760 mmHg |
Molecular Formula | C17H13BrN2 |
Molecular Weight | 325.20300 |
Flash Point | 276.4ºC |
Exact Mass | 324.02600 |
PSA | 24.06000 |
LogP | 5.41450 |
Index of Refraction | 1.688 |